Immunologic adverse reactions of β-blockers and the skin (Review)

Tatu,Alin   Laurentiu; Elisei,Alina   Mihaela; Chioncel,Valentin; Miulescu,Magdalena; Nwabudike,Lawrence   Chukwudi

doi:10.3892/etm.2019.7504

Immunologic adverse reactions of β-blockers and the skin (Review)

Authors:
- Alin Laurentiu Tatu
- Alina Mihaela Elisei
- Valentin Chioncel
- Magdalena Miulescu
- Lawrence Chukwudi Nwabudike
View Affiliations

Affiliations: Medical and Pharmaceutical Research Unit/Competitive, Interdisciplinary Research Integrated Platform ‘Dunărea de Jos’, ReForm-UDJG; Research Centre in the Field of Medical and Pharmaceutical Sciences, Faculty of Medicine and Pharmacy, Department of Pharmaceutical Sciences, ‘Dunărea de Jos’ University of Galați, 800010 Galati, Romania, Department of Cardio-Thoracic Pathology, Faculty of Medicine, ‘Carol Davila’ University of Medicine and Phamacy, 050474 Bucharest, Romania, Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos University’ of Galati, 800010 Galati, Romania, Department of Diabetic Foot Care, ‘Prof. N. Paulescu’ National Institute of Diabetes, 011233 Bucharest, Romania
Published online on: April 18, 2019 https://doi.org/10.3892/etm.2019.7504
Pages: 955-959
Copyright: © Tatu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haemangiomas, their potential positive effects in wound healing, Kaposi sarcoma, melanoma and pyogenic granuloma, and, more recently, pemphigus. Since β-blockers are deployed in a variety of disorders, which have cutaneous co-morbidities such as psoriasis, their pertinence to dermatologists cannot be overstated. Likewise, β-blockers, like any other drug category, carry risks of side effects, some of which are dermatologic. These include triggering and exacerbation of psoriasis, psoriatic and rheumatoid arthritis, anaphylaxis, contact dermatitis, occupational contact dermatitis, Raynaud's disease, alopecia, lichen planus-like drug eruption, hyperhydrosis and vitiligo. While recent articles have focussed on the positive uses of β-blockers, it may also be wise to call our attention to the potential dermatologic adverse effects that may follow β-blocker use, as well as possible therapeutic approaches to these. This short review will focus on those dermatoses resulting from β-blocker use, which have an immunologic basis.

View Figures

View References

1	Akbar S and Alorainy MS: The current status of β-blockers' use in the management of hypertension. Saudi Med J. 35:1307–1317. 2014.PubMed/NCBI
2	Pemberton P, Veenith T, Snelson C and Whitehouse T: Is it time to beta block the septic patient? Biomed Res Int. 2015:4243082015. View Article : Google Scholar : PubMed/NCBI
3	Loftus TJ, Efron PA, Moldawer LL and Mohr AM: β-blockade use for traumatic injuries and immunomodulation: A review of proposed mechanisms and clinical evidence. Shock. 46:341–351. 2016. View Article : Google Scholar : PubMed/NCBI
4	Nwabudike LC and Tatu AL: Response to chronic exposure to tetracyclines and subsequent diagnosis for non-melanoma skin cancer in a large Mid-Western US population. J Eur Acad Dermatol Venereol. 32:e1592018. View Article : Google Scholar : PubMed/NCBI
5	Tatu AL and Nwabudike LC: Bullous reactions associated with COX-2 inhibitors. Am J Ther. 24:e477–e480. 2017. View Article : Google Scholar : PubMed/NCBI
6	Gheorghe I, Tatu AL, Lupu I, Thamer O, Cotar AI, Pircalabioru GG, Popa M, Cristea VC, Lazar V and Chifiriuc MC: Molecular characterization of virulence and resistance features in Staphylococcus aureus clinical strains isolated from cutaneous lesions in patients with drug adverse reactions. Rom Biotechnol Lett. 22:12321–12327. 2017.
7	Happle R and Kluger N: Koebners sheep in Wolf's clothing: does the isotopic response exists as a distinct phenomenon? J Eur Acad Dermatol Venereol. 32:542–543. 2018. View Article : Google Scholar : PubMed/NCBI
8	Gambichler T, Rüddel I, Hessam S, Bechara FG, Stockfleth E and Schmitz L: Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. J Eur Acad Dermatol Venereol. 32:1485–1491. 2018. View Article : Google Scholar : PubMed/NCBI
9	Tantu M, Belu E, Bobescu E, Armean SM, Armean P, Constantin MM and Domnariu CD: Role of angiotensin converting enzyme (ACE) inhibitors in hypertension and cardiovascular protection management. Farmacia. 62:443–451. 2014.
10	Chen L and Tsai TF: The role of β-blockers in dermatological treatment: A review. J Eur Acad Dermatol Venereol. 32:363–371. 2018. View Article : Google Scholar : PubMed/NCBI
11	Sivamani RK, Lam ST and Isseroff RR: Beta adrenergic receptors in keratinocytes. Dermatol Clin. 25:643–653. 2007. View Article : Google Scholar : PubMed/NCBI
12	Yilmaz MB, Turhan H, Akin Y, Kisacik HL and Korkmaz S: Beta-blocker-induced psoriasis: A rare side effect - a case report. Angiology. 53:737–739. 2002. View Article : Google Scholar : PubMed/NCBI
13	O'Brien M and Koo J: The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 5:426–432. 2006.PubMed/NCBI
14	Tsankov N, Angelova I and Kazandjieva J: Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 1:159–165. 2000. View Article : Google Scholar : PubMed/NCBI
15	Sehgal VN, Dogra S, Srivastava G and Aggarwal AK: Psoriasiform dermatoses. Indian J Dermatol Venereol Leprol. 74:94–99. 2008. View Article : Google Scholar : PubMed/NCBI
16	Fry L and Baker BS: Triggering psoriasis: The role of infections and medications. Clin Dermatol. 25:606–615. 2007. View Article : Google Scholar : PubMed/NCBI
17	Halevy S and Livni E: Psoriasis and psoriasiform eruptions associated with propranolol - the role of an immunological mechanism. Arch Dermatol Res. 283:472–473. 1991. View Article : Google Scholar : PubMed/NCBI
18	Kim GK and Del Rosso JQ: Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 3:32–38. 2010.PubMed/NCBI
19	Shaw SM, Coppinger T, Waywell C, Dunne L, Archer LD, Critchley WR, Yonan N, Fildes JE and Williams SG: The effect of beta-blockers on the adaptive immune system in chronic heart failure. Cardiovasc Ther. 27:181–186. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wahle M, Krause A, Pierer M, Hantzschel H and Baerwald CG: Immunopathogenesis of rheumatic diseases in the context of neuroendocrine interactions. Ann NY Acad Sci. 966:355–364. 2002. View Article : Google Scholar : PubMed/NCBI
21	Eyre S, Bowes J, Potter C, Worthington J and Barton A: Association of the FCRL3 gene with rheumatoid arthritis: A further example of population specificity? Arthritis Res Ther. 8:R1172006. View Article : Google Scholar : PubMed/NCBI
22	Lubahn CL, Schaller JA, Bellinger DL, Sweeney S and Lorton D: The importance of timing of adrenergic drug delivery in relation to the induction and onset of adjuvant-induced arthritis. Brain Behav Immun. 18:563–571. 2004. View Article : Google Scholar : PubMed/NCBI
23	Härle P, Möbius D, Carr DJ, Schölmerich J and Straub RH: An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum. 52:1305–1313. 2005. View Article : Google Scholar : PubMed/NCBI
24	Fan X and Wang I: β2 Adrenergic receptor on T lymphocytes and its clinical implications. Prog Nat Sci. 19:17–23. 2009. View Article : Google Scholar
25	Tatu AL and Nwabudike LC: Metoprolol-associated onset of psoriatic arthropathy. Am J Ther. 24:e370–e371. 2017. View Article : Google Scholar : PubMed/NCBI
26	Newman BR and Schultz LK: Epinephrine-resistant anaphylaxis in a patient taking propranolol hydrochloride. Ann Allergy. 47:35–37. 1981.PubMed/NCBI
27	Nassiri M, Babina M, Dölle S, Edenharter G, Ruëff F and Worm M: Ramipril and metoprolol intake aggravate human and murine anaphylaxis: Evidence for direct mast cell priming. J Allergy Clin Immunol. 135:491–499. 2015. View Article : Google Scholar : PubMed/NCBI
28	van Beek LM, de Keizer RJ, Polak BCP, Elzenaar PR, van Haeringen NJ and Kijlstra A: Incidence of ocular side effects of topical β blockers in the Netherlands. Br J Ophthalmol. 84:856–859. 2000. View Article : Google Scholar : PubMed/NCBI
29	Cheong HI, Johnson J, Cormier M and Hosseini K: In vitro cytotoxicity of eight β-blockers in human corneal epithelial and retinal pigment epithelial cell lines: Comparison with epidermal keratinocytes and dermal fibroblasts. Toxicol In Vitro. 22:1070–1076. 2008. View Article : Google Scholar : PubMed/NCBI
30	Schallreuter KU: Beta-adrenergic blocking drugs may exacerbate vitiligo. Br J Dermatol. 132:168–169. 1995. View Article : Google Scholar : PubMed/NCBI
31	Wu CS, Yu HS, Chang HR, Yu CL, Yu CL and Wu BN: Cutaneous blood flow and adrenoceptor response increase in segmental-type vitiligo lesions. J Dermatol Sci. 23:53–62. 2000. View Article : Google Scholar : PubMed/NCBI
32	Tatu AL and Ionescu MA: Multiple autoimmune syndrome type III-thyroiditis, vitiligo and alopecia areata. Acta Endo Buc. 13:124–125. 2017. View Article : Google Scholar
33	Muramatsu K, Nomura T, Shiiya C, Nishiura K and Tsukinaga I: Alopecia induced by timolol eye-drops. Acta Derm Venereol. 97:295–296. 2017. View Article : Google Scholar : PubMed/NCBI
34	Botchkarev VA, Peters EM, Botchkareva NV, Maurer M and Paus R: Hair cycle-dependent changes in adrenergic skin innervation, and hair growth modulation by adrenergic drugs. J Invest Dermatol. 113:878–887. 1999. View Article : Google Scholar : PubMed/NCBI
35	Lewis RV and Lofthouse C: Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf. 9:272–279. 1993. View Article : Google Scholar : PubMed/NCBI
36	Fraunfelder FT, Meyer SM and Menacker SJ: Alopecia possibly secondary to topical ophthalmic β-blockers. JAMA. 263:1493–1494. 1990. View Article : Google Scholar : PubMed/NCBI
37	Richards S: Cutaneous side-effects of beta-adrenergic blockers. Australas J Dermatol. 26:25–28. 1985. View Article : Google Scholar : PubMed/NCBI
38	Shelley ED and Shelley WB: Alopecia and drug eruption of the scalp associated with a new beta-blocker, nadolol. Cutis. 35:148–149. 1985.PubMed/NCBI
39	England JR and England JD: Alopecia and propranolol therapy. Aust Fam Physician. 11:225–226. 1982.PubMed/NCBI
40	Hilder RJ: Propranolol and alopecia. Cutis. 24:63–64. 1979.PubMed/NCBI
41	Martin CM, Southwick EG and Maibach HI: Propranolol induced alopecia. Am Heart J. 86:236–237. 1973. View Article : Google Scholar : PubMed/NCBI
42	Bodmer M, Egger SS, Hohenstein E, Beltraminelli H and Krähenbühl S: Lichenoid eruption associated with the use of nebivolol. Ann Pharmacother. 40:1688–1690. 2006. View Article : Google Scholar : PubMed/NCBI
43	Meyer S, Burgdorff T, Szeimies RM, Vogt T, Landthaler M and Karrer S: Management of erosive lichen planus with topical tacrolimus and recurrence secondary to metoprolol. J Eur Acad Dermatol Venereol. 19:236–239. 2005. View Article : Google Scholar : PubMed/NCBI
44	Brănișteanu DE, Pintilie A, Dimitriu A, Cerbu A, Ciobanu D, Oanţă A and Tatu AL: Clinical, laboratory and therapeutic profile of lichen planus. Rev Med Chir Soc Med Nat Iasi. 121:25–32. 2017.(In Romanian).
45	Lage D, Juliano PB, Metze K, de Souza EM and Cintra ML: Lichen planus and lichenoid drug-induced eruption: A histological and immunohistochemical study. Int J Dermatol. 51:1199–1205. 2012. View Article : Google Scholar : PubMed/NCBI
46	Brănişteanu DE, Brănişteanu DC, Stoleriu G, Ferariu D, Voicu CM, Stoica LE, Căruntu C, Boda D, Filip-Ciubotaru FM, Dimitriu A, et al: Histopathological and clinical traps in lichen sclerosus: A case report. Rom J Morphol Embryol. 57 (Suppl 2):817–823. 2016.PubMed/NCBI
47	Tatu AL and Nwabudike LC: The treatment options of male genital lichen sclerosus et atrophicus: Treatments of Genital Lichen Sclerosus Conference. 14th National Congress of Urogynecology (Urogyn) Location: Eforie, Romania Date: Sep 07-09, 2017, . Proceedings of the 14th National Congress of Urogynecology and the National Conference of the Romanian Association for the Study of Pain. 262–264. 2017.
48	Aslan AN, Güney MC, Akçay M, Keleş T and Bozkurt E: Lichenoid type cutaneous hyperpigmentation induced by nebivolol. Turk Kardiyol Dern Ars. 45:268–270. 2017.PubMed/NCBI
49	Schmutz JL, Houet C, Trechot P, Barbaud A and Gillet-Terver MN: Sweating and beta-adrenoceptor antagonists. Dermatology. 190:861995. View Article : Google Scholar : PubMed/NCBI
50	Shields SA, MacDowell KA, Fairchild SB and Campbell ML: Is mediation of sweating cholinergic, adrenergic, or both? A comment on the literature. Psychophysiology. 24:312–319. 1987. View Article : Google Scholar : PubMed/NCBI
51	Lama PJ: Systemic adverse effects of beta-adrenergic blockers: An evidence-based assessment. Am J Ophthalmol. 134:749–760. 2002. View Article : Google Scholar : PubMed/NCBI
52	Ali FR, Shackleton DB, Kingston TP and Williams JD: Occupational exposure to propranolol: A rarely recognised cause of allergic contact dermatitis. Int J Occup Med Environ Health. 28:639–640. 2015. View Article : Google Scholar : PubMed/NCBI
53	Jappe U, Uter W, Menezes de Pádua CA, Herbst RA and Schnuch A: Allergic contact dermatitis due to beta-blockers in eye drops: A retrospective analysis of multicentre surveillance data 1993–2004. Acta Derm Venereol. 86:509–514. 2006. View Article : Google Scholar : PubMed/NCBI
54	Tatu AL: Topical steroid induced facial rosaceiform dermatitis. Acta Endo (Buc). 12:232–233. 2016. View Article : Google Scholar
55	Tatu AL, Ionescu MA, Clatici VG and Cristea VC: Bacillus cereus strain isolated from Demodex folliculorum in patients with topical steroid-induced rosaceiform facial dermatitis. An Bras Dermatol. 91:676–678. 2016. View Article : Google Scholar : PubMed/NCBI
56	Tatu AL, Ionescu MA and Nwabudike LC: Contact allergy to topical mometasone furoate confirmed by rechallenge and patch test. Am J Ther. 25:e497–e498. 2018. View Article : Google Scholar : PubMed/NCBI
57	Tatu AL and Clătici V: Some correlations between the clinical and dermoscopic features of steroid induced facial dermatitis. J Am Acad Dermatol. 72:912015. View Article : Google Scholar
58	Miyamoto D, Maruta CW, Santi CG, Zoroquiain P, Dias AB, Mansure JJ, Burnier MN Jr and Aoki V: Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris. J Eur Acad Dermatol Venereol. Feb 28–2018.(Epub ahead of print). doi: 10.1111/jdv.14903. View Article : Google Scholar
59	Abdelmaksoud A and Vestita M: Beta-blockers for treatment of autoimmune blistering dermatosis. J Eur Acad Dermatol Venereol. May 6–2018.(Epub ahead of print). doi: 10.1111/jdv.15054. View Article : Google Scholar
60	Prabha N, Chhabra N and Arora R: Beta-blockers in dermatology. Indian J Dermatol Venereol Leprol. 83:399–407. 2017. View Article : Google Scholar : PubMed/NCBI
61	Manu P and Rogozea LM: Propranolol for angina pectoris. Am J Ther. 23:e1285–e1286. 2016. View Article : Google Scholar : PubMed/NCBI
62	Bilewicz-Stebel M, Miziołek B, Bergler-Czop B and Stańkowska A: Drug-induced subacute cutaneous lupus erythematosus caused by a topical beta blocker - timolol. Acta Dermatovenerol Croat. 26:44–47. 2018.PubMed/NCBI
63	Pulitzer MP, Nolan KA, Oshman RG and Phelps RG: CD30⁺ lymphomatoid drug reactions. Am J Dermatopathol. 35:343–350. 2013. View Article : Google Scholar : PubMed/NCBI
64	Rogozea LM, Diaconescu DE, Dinu EA, Badea O, Popa D, Andreescu O and Leaşu FG: Bioethical dilemmas in using animal in medical research. Challenges and opportunities. Rom J Morphol Embryol. 56:1227–1231. 2015.PubMed/NCBI
65	Purcaru D, Preda A, Popa D, Moga MA and Rogozea L: Informed consent: How much awareness is there? PLoS One. 9:e1101392014. View Article : Google Scholar : PubMed/NCBI
66	Dumitriu BO, Fasie V, Mardare N, Diaconu C, Gurau G and Tatu AL: Formulation, preparation, physico-chimical analysis, microbiological peculiarities and therapeutic challenges of extractive solution of Kombucha. Rev Chim (Bucharest). 69:720–724. 2018.
67	Robu S, Chesaru BI, Diaconu C, Dumitriu BO, Tutunaru D, Stanescu U and Lisa EL: Lavandula hybrida: Microscopic characterization and the evaluation of the essential oil. Farmacia. 64:914–917. 2016.
68	Nwabudike LC: Case reports of acne and homeopathy. Complement Med Res. 25:52–55. 2018. View Article : Google Scholar : PubMed/NCBI
69	Nwabudike LC: Knowledge removes discomfort. JAMA Dermatol. 154:738–739. 2018. View Article : Google Scholar : PubMed/NCBI